AustralieFrV1, Main, Exploration, bibRecord, 005C87

Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations

Identifieur interne : 005C87 ( Main/Exploration ); précédent : 005C86; suivant : 005C88

Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations

Auteurs : Jennifer K. Rogers [Royaume-Uni] ; John J. V. Mcmurray [Royaume-Uni] ; Stuart J. Pocock [Royaume-Uni] ; Faiez Zannad [France] ; Henry Krum [Australie] ; Dirk J. Van Veldhuisen [Pays-Bas] ; Karl Swedberg [Suède] ; Harry Shi [États-Unis] ; John Vincent [États-Unis] ; Bertram Pitt [États-Unis]

Source :

Circulation : (New York, N.Y.) [ 0009-7322 ] ; 2012.

RBID : Pascal:12-0448039

Descripteurs français

Pascal (Inist)
- Insuffisance cardiaque, Pathologie de l'appareil circulatoire, Eplérénone, Homme, Hospitalisation, Antihypertenseur.
Wicri :
- topic : Homme, Hospitalisation.

English descriptors

KwdEn :
- Antihypertensive agent, Cardiovascular disease, Eplerenone, Heart failure, Hospitalization, Human.

Abstract

Background-Eplerenone is known to reduce time to first hospitalization for heart failure or cardiovascular death in patients with heart failure and mild symptoms. In chronic diseases such as heart failure, characterized by repeat hospitalizations, analyzing all heart failure hospitalizations, not just the first, should give a more complete picture of treatment benefits. Methods and Results-The Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) trial compared eplerenone with placebo in 2737 patients with mild heart failure, followed for a median 2.08 years (interquartile range, 1.08-3.10 years). Data were collected on all hospitalizations, with a focus on those due to heart failure. Heart failure hospitalization rates in the eplerenone and placebo groups were 10.70 and 16.99 per 100 patient-years, respectively. Allowing for skewness in the frequency of hospitalizations by using the negative binomial generalized linear model, the rate ratio (eplerenone versus placebo) was 0.53 (95% confidence interval, 0.42-0.66; P<0.0001). A plot of cumulative hospitalization rates over time revealed that most of the reduced risk on eplerenone occurred in the first year of follow-up. Several baseline variables strongly predicted the risk of hospitalization. More complex statistical methods, adjusting for mortality (as informative censoring), made a negligible difference in these findings. Conclusions-Eplerenone markedly reduces the risk of heart failure hospitalizations in patients with heart failure and mild symptoms to a greater extent than is captured by only studying the time to first hospitalization. Future clinical trials in heart failure would gain from incorporating repeat hospitalizations into their primary evaluation of treatment effects.

Affiliations:

Australie, France, Pays-Bas, Royaume-Uni, Suède, États-Unis
Angleterre, Grand Est, Grand Londres, Groningue (province), Lorraine (région), Victoria (État), Écosse
Glasgow, Groningue, Londres, Melbourne, Nancy
Université de Glasgow

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000E66
to stream PascalFrancis, to step Curation: 005055
to stream PascalFrancis, to step Checkpoint: 001161
to stream Main, to step Merge: 005F96
to stream Main, to step Curation: 005C87

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations</title>
<author><name sortKey="Rogers, Jennifer K" sort="Rogers, Jennifer K" uniqKey="Rogers J" first="Jennifer K." last="Rogers">Jennifer K. Rogers</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>University of Glasgow</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
<orgName type="university">Université de Glasgow</orgName>
</affiliation>
</author>
<author><name sortKey="Pocock, Stuart J" sort="Pocock, Stuart J" uniqKey="Pocock S" first="Stuart J." last="Pocock">Stuart J. Pocock</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Nancy University</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Grand Est</region>
<region type="old region">Lorraine (région)</region>
<settlement type="city">Nancy</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Monash Centre of Cardiovascular Research & Education in Therapeutics</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Sahlgrenska Academy, University of Gothenburg</s1>
<s2>Gothenburg</s2>
<s3>SWE</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<wicri:noRegion>Gothenburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shi, Harry" sort="Shi, Harry" uniqKey="Shi H" first="Harry" last="Shi">Harry Shi</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Pfizer</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pfizer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Pfizer</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pfizer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>University of Michigan Medical School</s1>
<s2>Ann Arbor, MI</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Michigan Medical School</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0448039</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0448039 INIST</idno>
<idno type="RBID">Pascal:12-0448039</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E66</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005055</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001161</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001161</idno>
<idno type="wicri:doubleKey">0009-7322:2012:Rogers J:eplerenone:in:patients</idno>
<idno type="wicri:Area/Main/Merge">005F96</idno>
<idno type="wicri:Area/Main/Curation">005C87</idno>
<idno type="wicri:Area/Main/Exploration">005C87</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations</title>
<author><name sortKey="Rogers, Jennifer K" sort="Rogers, Jennifer K" uniqKey="Rogers J" first="Jennifer K." last="Rogers">Jennifer K. Rogers</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>University of Glasgow</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
<orgName type="university">Université de Glasgow</orgName>
</affiliation>
</author>
<author><name sortKey="Pocock, Stuart J" sort="Pocock, Stuart J" uniqKey="Pocock S" first="Stuart J." last="Pocock">Stuart J. Pocock</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Nancy University</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Grand Est</region>
<region type="old region">Lorraine (région)</region>
<settlement type="city">Nancy</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Monash Centre of Cardiovascular Research & Education in Therapeutics</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Sahlgrenska Academy, University of Gothenburg</s1>
<s2>Gothenburg</s2>
<s3>SWE</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<wicri:noRegion>Gothenburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shi, Harry" sort="Shi, Harry" uniqKey="Shi H" first="Harry" last="Shi">Harry Shi</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Pfizer</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pfizer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Pfizer</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pfizer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>University of Michigan Medical School</s1>
<s2>Ann Arbor, MI</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Michigan Medical School</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Circulation : (New York, N.Y.)</title>
<title level="j" type="abbreviated">Circulation : (N. Y. N.Y.)</title>
<idno type="ISSN">0009-7322</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Circulation : (New York, N.Y.)</title>
<title level="j" type="abbreviated">Circulation : (N. Y. N.Y.)</title>
<idno type="ISSN">0009-7322</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antihypertensive agent</term>
<term>Cardiovascular disease</term>
<term>Eplerenone</term>
<term>Heart failure</term>
<term>Hospitalization</term>
<term>Human</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Insuffisance cardiaque</term>
<term>Pathologie de l'appareil circulatoire</term>
<term>Eplérénone</term>
<term>Homme</term>
<term>Hospitalisation</term>
<term>Antihypertenseur</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Hospitalisation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background-Eplerenone is known to reduce time to first hospitalization for heart failure or cardiovascular death in patients with heart failure and mild symptoms. In chronic diseases such as heart failure, characterized by repeat hospitalizations, analyzing all heart failure hospitalizations, not just the first, should give a more complete picture of treatment benefits. Methods and Results-The Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) trial compared eplerenone with placebo in 2737 patients with mild heart failure, followed for a median 2.08 years (interquartile range, 1.08-3.10 years). Data were collected on all hospitalizations, with a focus on those due to heart failure. Heart failure hospitalization rates in the eplerenone and placebo groups were 10.70 and 16.99 per 100 patient-years, respectively. Allowing for skewness in the frequency of hospitalizations by using the negative binomial generalized linear model, the rate ratio (eplerenone versus placebo) was 0.53 (95% confidence interval, 0.42-0.66; P<0.0001). A plot of cumulative hospitalization rates over time revealed that most of the reduced risk on eplerenone occurred in the first year of follow-up. Several baseline variables strongly predicted the risk of hospitalization. More complex statistical methods, adjusting for mortality (as informative censoring), made a negligible difference in these findings. Conclusions-Eplerenone markedly reduces the risk of heart failure hospitalizations in patients with heart failure and mild symptoms to a greater extent than is captured by only studying the time to first hospitalization. Future clinical trials in heart failure would gain from incorporating repeat hospitalizations into their primary evaluation of treatment effects.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>Suède</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Grand Est</li>
<li>Grand Londres</li>
<li>Groningue (province)</li>
<li>Lorraine (région)</li>
<li>Victoria (État)</li>
<li>Écosse</li>
</region>
<settlement><li>Glasgow</li>
<li>Groningue</li>
<li>Londres</li>
<li>Melbourne</li>
<li>Nancy</li>
</settlement>
<orgName><li>Université de Glasgow</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Rogers, Jennifer K" sort="Rogers, Jennifer K" uniqKey="Rogers J" first="Jennifer K." last="Rogers">Jennifer K. Rogers</name>
</region>
<name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name>
<name sortKey="Pocock, Stuart J" sort="Pocock, Stuart J" uniqKey="Pocock S" first="Stuart J." last="Pocock">Stuart J. Pocock</name>
</country>
<country name="France"><region name="Grand Est"><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name>
</region>
</country>
<country name="Australie"><region name="Victoria (État)"><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
</region>
</country>
<country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name>
</region>
</country>
<country name="Suède"><noRegion><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name>
</noRegion>
</country>
<country name="États-Unis"><noRegion><name sortKey="Shi, Harry" sort="Shi, Harry" uniqKey="Shi H" first="Harry" last="Shi">Harry Shi</name>
</noRegion>
<name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name>
<name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005C87 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005C87 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:12-0448039
   |texte=   Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations

Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri